The US-American Biotech company "Moderna" has been achieved with an experimental vaccine against the Corona a little bit of a breakthrough and wants to test this at the end of July to 30,000 volunteers.
In the first Phase of the clinical Tests have developed the subjects of the antibodies against the causative agent of Sars-CoV-2, explained that the study involved a National Institute for allergies and infectious diseases (NIAID).
In the case of the 45 participants in the age from 18 to 55 years, there have been no serious side effects, it was more.subjects showed "robust immune response"
The subjects were within two months, two injections of the vaccine, developed more neutralizing antibodies than persons for whom a Coronavirus was the infection been diagnosed, as it was called on Tuesday next. The researchers presented the results of a study in the "New England Journal of Medicine".
The manufacturer Moderna said in a message from a "robust immune response", which is now the way for much larger studies to efficacy levels.Corona vaccine is the end of July, Phase 3
The vaccine mRNA-1273 should be from the end of July at around 30,000 subjects tested in a so-called Phase 3 trial.
Due to the short study period was also not yet clear whether and how long the antibodies can protect the subjects, in fact, an infection with the Coronavirus. The blood of the participants should therefore be assessed on a regular basis on the proportion of antibodies, said the study.Worldwide, with high pressure to vaccines
the research in the World, there are numerous vaccine candidates in various stages. The tested active ingredients have different ways of function.
In the case of Modernas preparation, it is a so-called RNA vaccine. So far, worldwide, there are no Human vaccines, the use of this procedure.
Also, the Mainz-based Biopharma company Biontech and the US group Pfizer, are working on such a vaccine. They stated in the beginning of July, that subjects, BNT in the case of Tests of the Phase 1 in the United States after an injection of the experimental vaccine 162b1 effective antibodies have developed. Here, too, now larger Tests are expected to follow.
- LA Jackson et al. (2020): A SARS-CoV-2 mRNA vaccine – preliminary report. The New England Journal of Medicine DOI: 10.1056/NEJMoa2022483.
- NIAID (2020): Experimental COVID-19 Vaccine Safe, Generates Immune Response, NIAID-Sponsored Phase 1 Trial Tested the mRNA Vaccine, retrieved on 15.07.2020: https://www.niaid.nih.gov/news-events/experimental-covid-19-vaccine-safe-generates-immune-response
Deutsche Presse-Agentur (dpa)
*The post "COVID-19: Good results after the first Tests of the vaccine," published by FitForFun. Contact with the executives here.FitForFun Updated Date: 16 July 2020, 04:26